Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodified native saccharides, derivatives of the invention are preferentially selected during conjugation to carrier proteins, and conjugates of the derivatives show improved immunogenicity compared to native polysaccharides.

A poly-[1-4]-D-glucosamine derivative comprising [1-4]-D-glucosamine recurring units and comprising a fluoropolyether chain bound to the nitrogen atom in the C-2 position of at least one of the [1-4]-D-glucosamine recurring units.

There is provided a composition comprising an aminoalkyl glucosaminide phosphate compound or a pharmaceutically salt thereof and a buffer for use as an immunomodulator.

Various embodiments disclosed relate to treatment fluids comprising a compound of the formula (I): wherein G.sub.1, G.sub.2, L.sub.1, L.sub.2, L.sub.3, q, and r are defined herein. Various other embodiments relates to methods of treating subterranean formations with such treatment fluids. ##STR00001##

Several embodiments of NO releasing structures are disclosed. In some embodiments, the structures are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of these structures. The covalently modified polymer structures may be tailored to release nitric oxide in a controlled manner and are useful for treatment of various medical conditions.

A halogenated polysaccharide is provided having a halogen content of from about 1.0 wt. % to about 85 wt. % based on the total weight of the halogenated polysaccharide and having an average chain length of at least 6 monosaccharides. Methods of halogenating a polysaccharide to form a halogenated polysaccharide are provided that can be performed in the presence or absence of a proton solvent. Compositions such as articles of manufacture containing a halogenated polysaccharide and methods of producing such articles are also provided. The article of manufacture can also include one or more additional polymers, for example, polyvinylchloride (PVC). The article of manufacture can be, for example, a flooring tile, flooring plank, or carpet. Halogenated polysaccharides and products containing the same are bio-based, environmentally sustainable replacements or complements to existing polymers and polymer products.

A halogenated polysaccharide is provided having a halogen content of from about 1.0 wt. % to about 85 wt. % based on the total weight of the halogenated polysaccharide and having an average chain length of at least 6 monosaccharides. Methods of halogenating a polysaccharide to form a halogenated polysaccharide are provided that can be performed in the presence or absence of a proton solvent. Compositions such as articles of manufacture containing a halogenated polysaccharide and methods of producing such articles are also provided. The article of manufacture can also include one or more additional polymers, for example, polyvinylchloride (PVC). The article of manufacture can be, for example, a flooring tile, flooring plank, or carpet. Halogenated polysaccharides and products containing the same are bio-based, environmentally sustainable replacements or complements to existing polymers and polymer products.

The present invention provides a method to prepare polysaccharides from Hirsutella sinensis. The prepared polysaccharides can reduce hyperglycemia and insulin resistance, and can therefore be used to prevent and treat type 2 diabetes and related conditions.

A paramylon-based resin excellent in mechanical characteristics and thermoplasticity is provided. The present embodiment provides a paramylon-based resin in which hydrogen atoms of hydroxy groups of paramylon are substituted by linear saturated aliphatic acyl group having 14 or more carbon atoms as a long chain component and/or acyl group having 2 or 3 carbon atoms (acetyl group or/and propionyl group) as a short chain component, wherein the paramylon has a weight average molecular weight in the range of more than 140000 to 220000 and a molecular weight distribution (weight average molecular weight/number average molecular weight) of 6.5 or less, a protein content of the paramylon is 0.22% by mass to 5.0% by mass, and a degree of substitution (DS.sub.Lo) by the long chain component and a degree of substitution (DS.sub.Sh) by the short chain component satisfy the following expressions (S1), (L1) and (T1); 1.7≤DS.sub.Sh≤2.8 (S1), 0≤DS.sub.Lo≤0.4 (L1), 2.1≤DS.sub.Lo+DS.sub.Sh≤2.8 (T1).

The present disclosure relates to a biocompatible composition and a method for preparing the same, and a hybrid composition of β-glucan and hyaluronic acid is prepared by hybrid cross-linkage. The biocompatible composition of the present disclosure high stability against heat and bio-enzymes, and thus is capable of being used as a medical material.